Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study

por Call, Jerry, Scherzer, Norman J., Josephy, P. David, Walentas, Christopher
Publicado 2009

Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry

por Call, Jerry, Walentas, Christopher D, Eickhoff, Jens C, Scherzer, Norman
Publicado 2012

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

por Call, Jerry W., Wang, Yu, Montoya, Denisse, Scherzer, Norman J., Heinrich, Michael C.
Publicado 2019

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Regis...

por Call, Jerry W., Wang, Yu, Montoya, Denisse, Scherzer, Norman J., Heinrich, Michael C.
Publicado 2019

Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)

por Hauber, A Brett, Gonzalez, Juan Marcos, Coombs, John, Sirulnik, Andres, Palacios, David, Scherzer, Norman
Publicado 2011

Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members

por Montoya, Denisse, Call, Jerry W., Eshak, Jennily, Knox, Pete, Luedke, Maeven, Kaur, Sahibjeet, Rothschild, Sara, Garland, Mary, Scherzer, Norman J.
Publicado 2022